MEIP Insider Trading

Insider Ownership Percentage: 3.12%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

MEI Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at MEI Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

MEI Pharma Share Price & Price History

Current Price: $2.87
Price Change: Price Increase of +0.1 (3.61%)
As of 01/17/2025 04:54 PM ET

This chart shows the closing price history over time for MEIP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$2.87Closing price on 01/20/25:

MEI Pharma Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for MEI Pharma (NASDAQ:MEIP)

52.38% of MEI Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MEIP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$142kbought$19ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$60M-$40M-$20M$0$20M$40M$60MTotal InflowsTotal Outflows
MEI Pharma logo
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Read More on MEI Pharma

Today's Range

Now: $2.87
Low: $2.76
High: $2.87

50 Day Range

MA: $2.70
Low: $2.36
High: $3.14

52 Week Range

Now: $2.87
Low: $2.30
High: $5.06

Volume

18,720 shs

Average Volume

36,210 shs

Market Capitalization

$19.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Who are the company insiders with the largest holdings of MEI Pharma?

MEI Pharma's top insider shareholders include:
  1. Anson Funds Management Lp (Major Shareholder)
  2. Charles V Baltic III (Director)
Learn More about top insider investors at MEI Pharma.